Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.2852W HIGH $9.82
Volume
25.20 K
Value Traded
115.89 K
Short % Float
2.31%
-3.42%Week
-16.4%1 Month
-32.43%3 Month
-17.22%6 Month
-94.68%5 Year
-96.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
72.67 M
EPS (TTM)
-1.82
P/E Ratio
-
Ent. Value
61.47 M
Total Shares
17.16 M
Float Shares
8.76 M
Insiders
49.00%
Institutions
27.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VRCA Catalyst Timeline
Dated clinical, regulatory and corporate events for Verrica Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Verrica Pharmaceuticals Inc.
407Total events
12Upcoming
105Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Pooled AnalysisCantharidinApprovedClinical Data
Pooled analysis shows VP-102 complete clearance ~4x faster than vehicle regardless of disease duration
molluscum contagiosumsource ↗
▲Additional DataVP-315Clinical Data
Exploratory analysis of potential abscopal-like effect of VP-315 in untreated BCC tumors
basal cell carcinomasource ↗
▲Pooled AnalysisCantharidinApprovedClinical Data
Pooled analysis: YCANTH complete clearance ~4x faster than vehicle regardless of disease duration
molluscum contagiosumsource ↗
▲Enrollment MilestoneCantharidinApprovedTrial
COVE-3 exceeded 50% of target enrollment
common wartssource ↗
▲Interim AnalysisCantharidinApprovedTrial
Per-protocol interim statistical power analysis completed
common wartssource ↗
▲Partnership / LicenseCantharidinApprovedCorporate
Exclusive distribution agreement with Medomie Pharma for YCANTH in Israel
molluscum contagiosumsource ↗
▲Quarterly UpdateCantharidinApprovedCorporate
YCANTH dispensed applicator units grew to 19,626 in Q2 2026
molluscum contagiosumsource ↗
▲First Patient DosedCantharidinApprovedTrial
First U.S. patient dosed in COVE-3 trial
common wartssource ↗
▲First Patient DosedCantharidinApprovedTrial
First Japanese patient dosed in COVE-3 trial
common wartssource ↗
◆Oral PresentationPresentation
Verrica to present at H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
◆Poster PresentationVP-315Presentation
Poster presentation of VP-315 Phase 2 data at 2026 SID Annual Meeting
basal cell carcinomasource ↗
◆Late-BreakerVP-315Presentation
Late-breaking abstract accepted for VP-315 abscopal effect data at SID 2026
basal cell carcinomasource ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Corporate Update Conference Call
▲Enrollment MilestoneCantharidinApprovedTrial
Achieved over 50% of current targeted enrollment in COVE-2 trial
common wartssource ↗
▲Oral PresentationVP-315Presentation
Phase 2 data presented at SID Annual Meeting
basal cell carcinomasource ↗
▲Enrollment UpdateCantharidinApprovedTrial
Over 50% of targeted enrollment achieved in COVE-2
common wartssource ↗
●Trial InitiationCantharidinApprovedTrial
Long-term follow-up study COVE-4 enrolling U.S. patients
common wartssource ↗
◆Oral PresentationPresentation
Verrica to present at 25th Annual Needham Virtual Healthcare Conference
▲AbstractVP-315Presentation
Late-breaking abstract accepted for VP-315 Phase 2 exploratory data in BCC at SID 2026
basal cell carcinomasource ↗
●Trial InitiationCantharidinApprovedTrial
Initiation of second Phase 3 trial (COVE-3) in US and Japan expected
common wartssource ↗
◆Quarterly UpdateCorporate
Q4 and FY2025 financial results and corporate update conference call
▲EU MAA SubmissionCantharidinApprovedEx-US Regulatory
EMA alignment on regulatory path for YCANTH approval in EU without additional clinical studies
molluscum contagiosumsource ↗
▲Product LaunchCantharidinApprovedPost-Market
YCANTH launched in Japan by Torii Pharmaceutical
molluscum contagiosumsource ↗
◆Oral PresentationPresentation
Verrica to present at TD Cowen 46th Annual Health Care Conference
▲Product LaunchCantharidinApprovedPost-Market
Launch of YCANTH in Japan by partner Torii Pharmaceutical
molluscum contagiosumsource ↗
▲Equity OfferingCorporate
Completed $50 million financing and repayment of debt facility with OrbiMed
▲Product LaunchCantharidinApprovedPost-Market
YCANTH commercial launch in Japan by partner Torii Pharmaceutical
molluscum contagiosumsource ↗
▲Topline ReadoutCantharidinApprovedClinical Data
Topline results from COVE-1 Phase 2 trial
common wartssource ↗
◆Other Regulator MilestoneTO-208FiledEx-US Regulatory
Expected Japanese regulatory decision for YCANTH (TO-208) for molluscum contagiosum
molluscum contagiosumsource ↗
◆Oral PresentationVP-315Presentation
Plan to present additional genomic and immune response data for VP-315 at a scientific conference later this year
basal cell carcinomasource ↗
▲First Patient DosedCantharidinApprovedTrial
Targeted first patient enrolled in US for Phase 3 common warts program
common wartssource ↗
▲First Patient DosedCantharidinApprovedTrial
First patient dosed in global Phase 3 program for YCANTH in common warts anticipated by end of 2025
Common Wartssource ↗
◆Milestone PaymentCantharidinApprovedCorporate
Verrica to receive $10 million milestone payment from Torii upon approval of YCANTH for molluscum contagiosum in Japan
molluscum contagiosumsource ↗
◆FDA ApprovalCantharidinApprovedFDA Decision
Potential approval of YCANTH (TO-208) for molluscum contagiosum in Japan
molluscum contagiosumsource ↗
◆Timing GuidancePresentation
Goal to generate cash positive monthly operating results by end of 2025
▼Equity OfferingCorporate
Private placement financing of $50 million to retire debt and extend cash runway
▲FDA Feedback ReceivedVP-315FDA Meeting
FDA positive feedback on Phase 3 study design for VP-315 in BCC
basal cell carcinomasource ↗
●Oral PresentationVP-315Presentation
New VP-315 data presented at Society for Immunotherapy of Cancer conference
basal cell carcinomasource ↗
▲EU MAA SubmissionCantharidinApprovedEx-US Regulatory
EMA positive feedback supports MAA filing for YCANTH in molluscum without additional Phase 3
molluscum contagiosumsource ↗
Past FDA Catalysts and PDUFA Decisions
How VRCA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-15 | VP-315 (ruxotemitide) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$3M
Pipeline Value
$30M
Commercial Value
Overvalued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 78%
Micro Cap(rank 513 of 658)
Percentile Rank
Verrica Pharmaceuticals Inc. faces pipeline headwinds (27/100), with $242M risk-adjusted pipeline value, led by VP-315 3 Day Dosing/Week in Basal Cell Carcinoma (Phase 2), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $30.3M x 1.0 = $30M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| YCANTH | $17M | $6M | +160.9% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VP-315 3 Day Dosing/Week Small moleculeCompletedNCT05188729 | Basal Cell Carcinoma | Phase 2 | COMPLETED | 92 | Apr 15, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every VRCA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| YCANTH Accelerated | molluscum contagiosum | Phase 3 | 2026-09-30 | Subjects treated with VP-102 achieved complete clearance at an approximately 4-fold faster rate than vehicle (HR=4.06; 95% CI, 2.94 · 5.74); Kaplan-Meier cumulative complete clearance by Day 84 was 60.1% with VP-102 versus 19.9% with vehicleRead More | Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology ConferencesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rosenberg Noah L.Officer (CMO) | Buy | 2,030 8,587 held | $4.92 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VRCA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.2 % | 4.33 M | 707.34 K |
VRCA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VRCA ranks across every disease it competes in
Competitive Position is a premium feature
See how VRCA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVRCA News
VRCA▲ +7.5%on this news
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
Verrica Pharmaceuticals announced the presentation of new data on YCANTH at two upcoming dermatology conferences. The data indicates that YCANTH achieves complete clearance of molluscum contagiosum approximately four times faster than the vehicle treatment. This reinforces the drug's profile as a new standard of care, encouraging early intervention in treatment.
Read more →VRCAVerrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
Verrica Pharmaceuticals announced it will present data on YCANTH and VP-315 at two dermatology conferences in September 2026. A post-hoc analysis revealed that YCANTH provides significant treatment benefits for molluscum contagiosum, regardless of disease duration. Additionally, VP-315 showed promising results in a Phase 2 trial for basal cell carcinoma, suggesting potential immune benefits.
Read more →VRCAVerrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Verrica Pharmaceuticals announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14, 2026. CEO Jayson Rieger will present at the event, highlighting the company's commitment to engaging with investors. Verrica focuses on developing treatments for dermatological diseases, including skin cancers and molluscum contagiosum.
Read more →VRCAVerrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
Verrica Pharmaceuticals has completed enrollment for its pivotal Phase 3 trial (COVE-2) evaluating YCANTH® for treating common warts. The interim analysis confirmed no additional patients are needed for enrollment. The company anticipates topline data by Q1 2027, with a second trial (COVE-3) also progressing well. This development is crucial for addressing a significant unmet need in dermatology.
Read more →VRCA▼ -5.2%on this news
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
Verrica Pharmaceuticals reported strong financial results for Q2 2026, with record demand for its product YCANTH, which saw a 28.3% increase in dispensed applicator units. The company anticipates topline data from its global Phase 3 program for common warts in mid-2027. Despite a net loss of $13.2 million, Verrica's cash runway is projected to extend into 2028 due to a new credit facility.
Read more →VRCA▼ -5.2%on this newsshared move
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
Verrica Pharmaceuticals has closed a credit facility of up to $27.5 million, aimed at supporting the commercialization of YCANTH and its global Phase 3 program for treating common warts. The facility, provided by Chairman Paul B. Manning, allows for no scheduled interest or principal payments until maturity in December 2030. This funding is expected to enhance the company's cash runway into 2028 and facilitate pivotal studies with data readouts anticipated by mid-2027.
Read more →VRCAVerrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Verrica Pharmaceuticals Inc. will host a conference call on August 6, 2026, to report its financial results for Q2 2026 and provide a corporate update. The call will be accessible via telephone and a live audio webcast. The company is known for its innovative treatments for dermatological diseases, including its FDA-approved product YCANTH® (VP-102).
Read more →VRCAVerrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Verrica Pharmaceuticals has entered into an exclusive agreement with Medomie Pharma to distribute YCANTH for treating molluscum contagiosum in Israel. This partnership aims to improve patient access to this FDA-approved treatment. Verrica retains global rights outside Japan and Israel and will receive a percentage of sales along with potential milestone payments.
Read more →VRCAVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals has announced the dosing of the first U.S. patient in the COVE-3 pivotal clinical trial for YCANTH (VP-102), aimed at treating common warts. This trial is part of a global Phase 3 program, which also includes a Japanese trial with Torii Pharmaceutical. The company aims to address the significant unmet need in dermatology, with common warts affecting millions annually.
Read more →VRCAVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Verrica Pharmaceuticals Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Jayson Rieger will discuss the company's advancements in dermatological therapeutics, including their FDA-approved treatment for molluscum contagiosum. The event will be accessible via a live webcast, with a replay available for 90 days.
Read more →VRCAVerrica Pharmaceuticals Reports First Quarter 2026 Financial Results
Verrica Pharmaceuticals reported strong financial results for Q1 2026, with significant growth in demand for its product YCANTH, which saw a 12.1% increase in dispensed units from the previous quarter. The company also achieved over 50% enrollment in its Phase 3 trial for common warts and expanded its market presence with a launch in Japan. Total revenue reached $5.0 million, reflecting a positive trend in the company's performance.
Read more →VRCAVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Verrica Pharmaceuticals will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. CEO Jayson Rieger will discuss the company's advancements in dermatological therapeutics, including its FDA-approved treatment for molluscum contagiosum. The event will be accessible via a live webcast and will be available for replay afterward.
Read more →VRCA▲ +17.7%on this news
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Verrica Pharmaceuticals announced the presentation of Phase 2 data on VP-315, highlighting its potential abscopal effects in treating basal cell carcinoma. The data, to be presented at the 2026 SID Annual Meeting, showed significant tumor size reduction in untreated lesions. The findings suggest VP-315 could offer a non-surgical option for patients with multiple tumors.
Read more →VRCA▲ +12.6%on this news· ran to +33% by day 1shared move
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
Verrica Pharmaceuticals Inc. will host a conference call on May 12, 2026, to discuss its first quarter financial results and provide a corporate update. The call will be accessible via telephone and a live audio webcast. Verrica is known for its FDA-approved treatment for molluscum contagiosum and is developing additional therapies for skin cancers.
Read more →VRCA▼ -12.3%on this news
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
Verrica Pharmaceuticals announced the acceptance of a late-breaking abstract for VP-315, an oncolytic peptide, at the 2026 Society for Investigative Dermatology Annual Meeting. The abstract highlights Phase 2 exploratory data suggesting a potential abscopal effect in treating basal cell carcinoma. This presentation underscores the importance of VP-315 as a promising non-surgical option for patients.
Read more →VRCA▲ +9.3%on this newsshared move
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Jayson Rieger will discuss the company's advancements in dermatological therapeutics, including their FDA-approved treatment for molluscum contagiosum. The event will be accessible via a live webcast, with a replay available for 90 days post-event.
Read more →VRCAVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Verrica Pharmaceuticals reported significant financial growth in 2025, with YCANTH net revenue increasing by 130% to $15.3 million. The company experienced a substantial rise in applicator unit sales and successfully reduced operating expenses. Advancements in their clinical pipeline include the initiation of a Phase 3 study for YCANTH and ongoing development of VP-315 for basal cell carcinoma. Moreover, Verrica gained regulatory alignment for YCANTH's approval process in the EU, enhancing its strategic outlook and partnerships.
Read more →VRCAVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Verrica Pharmaceuticals Inc. will hold a conference call on March 11, 2026, to report its financial results for the fourth quarter and full year of 2025. The call will provide updates on the company's performance and ongoing developments in dermatology therapeutics. Notably, Verrica's product YCANTH® is the first FDA-approved treatment for molluscum contagiosum.
Read more →VRCAVerrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Verrica Pharmaceuticals Inc. will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026. CEO Jayson Rieger will lead the presentation, which can be accessed via a live webcast. The company is known for its FDA-approved treatment for molluscum contagiosum and is developing additional dermatological therapies.
Read more →About Verrica Pharmaceuticals Inc.
Headquarters44 WEST GAY STREET, WEST CHESTER, PA
BIOPHARMAWATCH ELITE PLUS
Trade the next VRCA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime